Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line therapy for adults with primary biliary cholangitis (PBC). The oral treatment is cleared for use in combination with the first-line PBC therapy ursodeoxycholic acid (UDCA) in patients who don’t adequately respond […] The post Seladelpar approved in Canada as Lyvdelzi to treat adults with PBC appeared first on Liver Disease News.
